Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Silo Pharma Inc
(NQ:
SILO
)
1.180
+0.020 (+1.72%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Jun 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Silo Pharma Inc
< Previous
1
2
3
4
5
Next >
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Closes on $2M Registered Direct Offering, Provides Update on SP-26 Ketamine Implant Therapeutic
June 07, 2024
Via
Investor Brand Network
Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia
June 07, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
June 06, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Enters Registered Direct Offering Estimated to Reach $2M
June 05, 2024
Via
Investor Brand Network
Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
June 05, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Pre-IND Submission for Proprietary Treatment for PTSD, Anxiety
June 04, 2024
Via
Investor Brand Network
Exposures
Product Safety
Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety
June 04, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Silo Pharma’s (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors
June 04, 2024
Via
AB Newswire
Exposures
Product Safety
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Shares ‘Significant Development’ in Depression Study Showing Potential to Extend Remission Period, Prevent Relapse
May 21, 2024
Via
Investor Brand Network
Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention
May 21, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Announces Participation in FDA Event Exploring Emerging Therapeutic Interest in Ketamine
May 14, 2024
Via
Investor Brand Network
Exposures
Product Safety
Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
May 14, 2024
Silo’s SP-26 currently in development utilizes ketamine as primary therapeutic agent
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Shares Positive Results for PTSD Treatment
April 23, 2024
Via
Investor Brand Network
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
April 23, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Plans for Exclusive Licensing of Novel Therapeutic for Alzheimer’s Disease
April 10, 2024
Via
Investor Brand Network
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
April 10, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Exercises Option for Exclusive License Agreement for SPC-15
March 20, 2024
Via
Investor Brand Network
Exposures
Product Safety
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
March 20, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent Application for Groundbreaking Ketamine Implant Therapeutic
March 18, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
March 18, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Completes Successful Dose-Ranging Study in Advancement of SPC-15
February 28, 2024
Via
Investor Brand Network
Exposures
Product Safety
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
February 28, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Validation of Delivery System for SP-26
February 14, 2024
Via
Investor Brand Network
Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
February 14, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Prioritize Clinical Pipeline Targeting Mental Health, Chronic Pain and Neurology
February 01, 2024
Via
Investor Brand Network
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
February 01, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Highlights Positive Results of Alzheimer’s Study
January 24, 2024
Via
Investor Brand Network
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
January 24, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Successfully Completes First Phase of Dose-Ranging SPC-15 Study
January 04, 2024
Via
Investor Brand Network
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
January 04, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.